Clinical trial · no report yet · Phase 3
CheckMate 648
A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
- NCT03143153 ↗
- Completed
- Bristol-Myers Squibb
- 49 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 23 | |
| Podcasts | 14 | |
| YouTube | 12 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Various Advanced Cancer
- Interventions
- Nivolumab; Ipilimumab; Cisplatin; Fluorouracil
- Arms
- Nivolumab + Ipilimumab · Experimental
- Nivolumab + Cisplatin + Fluorouacil · Experimental
- Cisplatin + Fluorouracil · Active comparator
- Enrollment
- 970
- Primary outcomes
- Overall Survival (OS) in Participants With Tumor Cell PD-L1
- Progression-free Survival (PFS) as Assessed by BICR in Participants With Tumor Cell PD-L1
- Sponsor
- Bristol-Myers Squibb with Ono Pharmaceutical Co., Ltd.
- Start
- Jun 29, 2017
- Primary completion
- Jan 18, 2021
- Results posted
- Yes
- Registry record
- NCT03143153 · updated Feb 17, 2026
Publications
linked from the registry- Zhang Y, Li C, Du K, Pengkhun N, Huang Z, Gong M, Li Y, Liu X, Li L, Wang D, Wang C, Chen F, Li J. Comparative analysis of immune checkpoint inhibitors in first-line treatment of esophageal squamous cell carcinoma: a network meta-analysis. Immunotherapy. 2023 Jul;15(10):737-750. doi: 10.2217/imt-2022-0236. Epub 2023 May 4. PubMed 37139963
- Kato K, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, Kojima T, Shirakawa Y, Okada M, Ishihara R, Kubota Y, Amaya-Chanaga C, Chen T, Matsumura Y, Kitagawa Y. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50). Esophagus. 2023 Apr;20(2):291-301. doi: 10.1007/s10388-022-00970-1. Epub 2022 Nov 19. PubMed 36401133
- Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y; CheckMate 648 Trial Investigators. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380. PubMed 35108470